thy/liv-SCID-hu mice: A system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues

Journal of Infectious Diseases

Volumn 177, Issue 2, 1998, Pages 337-346

  Pettoello Mantovani, Massimo ^b   Kollmann, Tobias R ^b   Katopodis, Nikos F ^b   Raker, Christina ^b   Kim, Ana ^b   Yurasov, Sergey ^b   Wiltshire, Hugh ^b   Goldstein, Harris ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FETUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; THYMUS; VIREMIA;

EID: 0031883198     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514214     Document Type: Article

References (16)

1. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
2. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995:345:952-5.
3. Markowitz M, Saag M, Powderly WG. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995:333:1534-9.
4. AIDS Clinical Trials Group, Collier AC, Coombs RW, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1995;333:1528-33.
5. Richman DD. HIV therapeutics. Science 1996;272:1886-8.
6. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
7. Pantaleo G, Graziosi C, Demerest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Science 1993;362:355-8.
8. Embretson J, Zupanic M, Ribas JL. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Science 1993; 362:359-62.
9. McCune JM, Peault B, Streeter PR, Rabin L. Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse. Immunol Rev 1991;124:45-62.
10. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM. Infection of the SCID-hu mouse by HIV-1. Science 1988;242:1684-6.
11. Kollmann TR, Pettoello-Mantovani M, Zhuang X, et al. Disseminated HIV-1 infection in SCID-hu mice after peripheral inoculation with HIV-1. J Exp Med 1994; 179:513-22.
12. Kollmann TR, Kim A, Pettoello-Mantovani M, et al. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. J Immunol 1995; 154:907-21.
13. Kollmann TR, Pettoello-Mantovani M, Katopodis N, et al. Demonstration of in vivo inhibition of HIV infection by treatment of SCID-hu mice with IL-10. Proc Natl Acad Sci USA 1996;93:3126-31.
14. Ho DD, Toyoshima T, Mo H, et al. Characterization of HIV-1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 1994;68:2016-20.
15. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11:F29-33.
16. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome p450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1995;277: 423-31.